Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma

Clinical and Translational Oncology

Volumn 14, Issue 4, 2012, Pages 271-279

  Himoudi, Nourredine ^a   Wallace, Rebecca ^a   Parsley, Kathryn L ^a   Gilmour, Kimberly ^a   Barrie, Alpha Umaru ^b   Howe, Karen ^b   Dong, Rong ^a   Sebire, Neil J ^b   Michalski, Antony ^b   Thrasher, Adrian J ^a   Anderson, John ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Dendritic cell vaccination; Osteosarcoma; Paediatric cancer

Indexed keywords

AUTOLOGOUS TUMOR LYSATE PULSED DENDRITIC CELL VACCINE; CANCER VACCINE; CD14 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANZYME B; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; PARACETAMOL; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD CLOTTING; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL MATURATION; CELL VIABILITY; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; EWING SARCOMA; FEASIBILITY STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; INJECTION SITE INDURATION; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; VACCINATION;

ADOLESCENT; ADULT; CANCER VACCINES; DENDRITIC CELLS; FEASIBILITY STUDIES; FEMALE; GRANZYMES; HEMOCYANIN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; OSTEOSARCOMA; PHENOTYPE; RECURRENCE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84860759062     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0795-1     Document Type: Article

References (20)

1. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332 (Pubitemid 28144092)
2. Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678 (Pubitemid 30002348)
3. Berntsen A, Geertsen PF, Svane IM (2006) Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50:34-43 (Pubitemid 43850125)
4. Suminoe A, Matsuzaki A, Hattori H et al (2009) Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant 13:746-753
5. Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26:633-638 (Pubitemid 351264359)
6. Palmerini E, Staals EL, Ferrari S et al (2008) Nonresectable multiple lung metastases of highgrade osteosarcoma of the humerus: stable after twelve years. A case report. J Bone Joint Surg Am 90:2240-2244
7. Ribas A, Comin-Anduix B, Chmielowski B et al (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-6276
8. Geiger JD, Hutchinson RJ, Hohenkirk LF et al (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513-8519 (Pubitemid 33131133)
9. Dohnal AM, Witt V, Hugel H et al (2007) Phase I study of tumor Ag-loaded IL-12 secreting semimature DC for the treatment of pediatric cancer. Cytotherapy 9:755-770 (Pubitemid 350226755)
10. Caruso DA, Orme LM, Neale AM et al (2004) Results of a phase 1 study utilizing monocytederived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6:236-246 (Pubitemid 39136507)
11. Brown M, Zhang Y, Dermine S et al (2000) Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Ther 7:1680-1689
12. Geiger J, Hutchinson R, Hohenkirk L et al (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356: 1163-1165
13. Matsuzaki A, Suminoe A, Hattori H et al (2002) Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 24:220-223 (Pubitemid 34297567)
14. Ardon H, De Vleeschouwer S, Van Calenbergh F et al (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:519-525
15. Berard F, Blanco P, Davoust J et al (2000) Crosspriming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192:1535-1544
16. Rubio MT, Means TK, Chakraverty R et al (2005) Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. Int Immunol 17:1561-1572 (Pubitemid 41754679)
17. Shilyansky J, Jacobs P, Doffek K et al (2007) Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. J Pediatr Surg 42:54-61; discussion 61 (Pubitemid 46037713)
18. Harris SG, Padilla J, Koumas L et al (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144-150 (Pubitemid 34178297)
19. Chizzolini C, Chicheportiche R, Alvarez M et al (2008) Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112:3696-3703
20. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A et al (2009) Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFNgamma production by memory CD4+ T cells. Eur J Immunol 39:1301-1312